In this study, we show that ganetespib suppresses NSCLC cell proliferation through inhibition of Grp94 and that combination of FBXL2 activation and Grp94 inhibition exhibits strong growth suppression effects on EGFR-mutated NSCLC. Here, FBXL2 is linked to non-small cell lung carcinoma.